Abi-Dargham, A. (2002) Recent evidence for dopamine abnormalities in schizophrenia. European Psychiatry, 17, 341–347.
Anonymous (2004) Atypical antipsychotics in schizophrenia. Drugs and Therapeutics Bulletin (August), 57–60.
Arvanitis, L. A., Miller, B. G. & the Seroquel Trial Study Group (1997) Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry, 42, 233–246.
Barnas, C., Stuppack, C. H., Miller, C.
et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms, a double blind trial versus haloperidol. International Clinical Psychopharmacology, 7, 23–27.
Bowles, T. M. & Levin, G. M. (2003) Aripiprazole: a new atypical antipsychotic drug. Annals of Pharmacotherapy, 37, 687–694.
Buchanan, R. W., Kreyenbuhl, J., Zito, J. M.
et al (2002) Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. American Journal of Psychiatry, 159, 1035–1043.
Buse, J. B. (2002) Metabolic side-effects of antipsychotics: focus on hyperglycaemia and diabetes. Journal of Clinical Psychiatry, 63 (suppl. 4), 37–41.
Cowen, P. J. (2005) New drugs, old problems. Advances in Psychiatric Treatment, 11, 19–27.
Czekalla, J., Kollach-Walker, S. & Beasley, C.M. (2001) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Journal of Clinical Psychiatry, 62, (suppl. 2), 35–40.
Davis, J. M. (1975) Overview: maintenance therapy in psychiatry. 1: Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.
Davis, J. M. & Casper, R. (1977) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs, 14, 260–282.
Drake, R. E., Essock, S. M., Shaner, A.
et al (2001) Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52, 469–476.
Edwards, J. G. (2005) Newer v. older antidepressants in long-term pharmacotherapy. Revisiting… Prevention of relapse and recurrence of depression. Advances in Psychiatric Treatment, 11, 184–194.
Gournay, K. (2005) The changing face of psychiatric nursing. Advances in Psychiatric Treatment, 11, 6–11.
Green, B. (2000) Focus on risperidone. Current Medical Research and Opinion, 16, 57–65.
Henderson, D. C. (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?
CNS Drugs, 16, 77–89.
Hunt, G. E., Bergen, J. & Bashir, M. (2002) Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophrenia Research, 54, 253–264.
Hwang, T. J., Lin, S. K. & Lin, H.-N. (2001) Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. Journal of the Formosan Medical Association, 100, 811–816.
Joffe, G., Appelberg, B. & Rimon, R. (1999) Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study. International Clinical Psychopharmacology, 14, 233–238.
Kerwin, R. W. & Bolonna, A. (2005) Management of clozapine-resistant schizophrenia. Advances in Psychiatric Treatment, 11, 101–106.
Kopelowicz, A., Zarate, R., Tripodis, K.
et al (2000) Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. American Journal of Psychiatry, 157, 987–993.
Lacro, J. P., Dunn, L. B., Dolder, C. R.
et al (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892–909.
Lane, H. Y., Chiu, W. C., Chou, J. C.
et al (2000) Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Journal of Clinical Psychiatry, 61, 209–214.
Lerner, V., Libov, I., Kotler, M.
et al (2004) Combination of atypical antipsychotic medication in the management of treatment resistant schizophrenia and schizoaffective disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 89–98.
Leucht, S., Pitschel-Walz, G., Abraham, D.
et al (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51–68.
Leucht, S., Kissling, W. & McGrath, J. (2004) Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry, 65, 177–186.
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.
Margolese, H. C., Malchy, L., Negrete, J. C.
et al (2002) Drug and alcohol use among patients with schizophrenia and related psychosis: levels and consequences. Schizophrenia Research, 67, 157–166.
Moller, H.-J. (2000) Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatrica Scandinavica, Supplementum, 400, 17–22.
Mortimer, A. (1997) Treatment of the patient with long-term schizophrenia. Advances in Psychiatric Treatment, 3, 339–346.
Mortimer, A. M. (2001) Pharmacological treatment approaches. In Managing Negative Symptoms of Schizophrenia (eds Mortimer, A. & Spence, S.) pp. 47–59. London: Science Press.
Mortimer, A. M., Martin, C., Wheeler, J. A.
et al (2003) Antipsychotic prescription in unipolar depression. 2: Withdrawing antipsychotics in unipolar, non-psychotic patients. Journal of Clinical Psychiatry, 64, 668–672.
Munro, J., O'Sullivan, D., Andrews, C.
et al (1999) Beyond pharmacovigilance: active monitoring of 2,760 patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry, 175, 576–580.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (Technology Appraisal Guidance no. 43). London: NICE.
Noordsy, D. L. & Green, A. I. (2003) Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports, 5, 340–346.
Peuskens, J. & Link, C. G. G. (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandanavica, 96, 265–273.
Pilling, S., Bebbington, P., Kuipers, E.
et al (2002a) Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine, 32, 763–782.
Pilling, S., Bebbington, P., Kuipers, E.
et al (2002b) Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychological Medicine, 32, 783–791.
Raniwalla, J., Tweed, J. A., Dollfus, S.
et al (1996) A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic in patients with acute exacerbation of schizophrenia. Schizophrenia Research, 18, 133.
Robinson, D. G., Woerner, M. G., McMeniman, M.
et al (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 473–479.
Rosebush, P. I. (2004) Treatment of catatonia. In Catatonia: from Psychopathology to Neurobiology (eds Caroff, S. N., Mann, S. C., Francis, A.
et al), pp. 141–150. Washington, DC: American Psychiatric Publishing.
Rosenthal, M. H. & Bryant, S. L. (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clinical Neuropharmacology, 27, 38–43.
Russell, J. M. & Mackell, J. A. (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs, 15, 537–551.
Seivewright, N., McMahon, C. & Egleston, P. (2005) Stimulant use still going strong. Revisiting… Misuse of amphetamines and related drugs. Advances in Psychiatric Treatment, 11, 262–269.
Sensky, T., Turkington, D., Kingdon, D.
et al (2000) A randomized controlled trial of cognitive–behavioural therapy for persistent symptoms in schizophrenia resistant to medication. Archives of General Psychiatry, 57, 165–172.
Silver, H. S. N. (1998) Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. Journal of Clinical Psychopharmacology, 18, 208–211.
Singh, S. P. & Fisher, H. L. (2005) Early intervention in psychosis: obstacles and opportunities. Advances in Psychiatric Treatment, 11, 71–78.
Siris, S. G. (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry, 163 (suppl. 22), 66–78.
Small, J. G., Clapper, M. H., Malloy, F. W.
et al (2003) Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology, 23, 223–228.
Song, F. (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. Journal of Psychopharmacology, 11, 65–71.
Stahl, S. M. & Grady, M. M. (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry – Central Nervous System Agents, 11, 313–327.
Swafford, C. D., Scheller-Gilkey, G., Miller, A. H.
et al (2000) Double jeopardy: schizophrenia and substance abuse. American Journal of Drug and Alcohol Abuse, 26, 343–353.
Taylor, D. M. & McAskill, R. (2000) Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica, 101, 416–432.
Tiihonen, J., Hallikainen, T., Ryynanen, O.-P.
et al (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry, 54, 1241–1248.
Tsuang, J. & Fong, T. W. (2004) Treatment of patients with schizophrenia and substance abuse disorders. Current Pharmaceutical Design, 10, 2249–2261.
Wassef, A. A., Hafiz, N. G., Hampton, D.
et al (2001) Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. Journal of Clinical Psychopharmacology, 21, 21–26.
Weiden, P., Aquila, A. & Standard, J. (1996) Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57 (suppl. 11), 53–60.
Winterer, G. & Hermann, W. M. (2000) Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry, 33, 182–188.